Omnicell, Inc. (NASDAQ:OMCL) Receives Average Rating of “Moderate Buy” from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has earned an average rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $57.8571.

Several analysts have recently commented on OMCL shares. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Wells Fargo & Company decreased their price target on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. KeyCorp reissued an “overweight” rating on shares of Omnicell in a report on Monday. Finally, Zacks Research lowered Omnicell from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th.

Institutional Trading of Omnicell

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Omnicell during the 2nd quarter valued at approximately $313,044,000. California State Teachers Retirement System grew its holdings in shares of Omnicell by 4,074.3% during the second quarter. California State Teachers Retirement System now owns 2,100,621 shares of the company’s stock valued at $87,218,000 after buying an additional 2,050,298 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Omnicell by 156.4% during the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after buying an additional 1,265,818 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Omnicell in the 3rd quarter valued at $25,625,000. Finally, First Light Asset Management LLC purchased a new position in Omnicell in the 1st quarter worth $16,351,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

OMCL stock opened at $33.41 on Friday. Omnicell has a one year low of $29.06 and a one year high of $55.00. The firm has a 50-day simple moving average of $39.92 and a two-hundred day simple moving average of $39.37. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of 39.77, a PEG ratio of 0.84 and a beta of 0.98.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. During the same period last year, the firm earned $0.45 earnings per share. Omnicell’s revenue was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, equities analysts forecast that Omnicell will post 1.41 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.